282TiP - Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study
| Autor: | Fasching, P.A., Decker, T., Guderian, G., Heim, J., Jackisch, C., Lueck, H.-J., Lüftner, D., Marmé, F., Reimer, T., Woeckel, A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|